0001689375-22-000030.txt : 20220923 0001689375-22-000030.hdr.sgml : 20220923 20220923165742 ACCESSION NUMBER: 0001689375-22-000030 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220921 FILED AS OF DATE: 20220923 DATE AS OF CHANGE: 20220923 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: KREHER NERISSA CENTRAL INDEX KEY: 0001741850 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40969 FILM NUMBER: 221262863 MAIL ADDRESS: STREET 1: C/O AVROBIO, INC. STREET 2: ONE KENDALL SQ., BLDG. 300, STE. 201 CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Entrada Therapeutics, Inc. CENTRAL INDEX KEY: 0001689375 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 813983399 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 6 TIDE STREET CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 857-305-1825 MAIL ADDRESS: STREET 1: 6 TIDE STREET CITY: BOSTON STATE: MA ZIP: 02210 FORMER COMPANY: FORMER CONFORMED NAME: CycloPorters, Inc. DATE OF NAME CHANGE: 20161104 4 1 wf-form4_166396664564604.xml FORM 4 X0306 4 2022-09-21 0 0001689375 Entrada Therapeutics, Inc. TRDA 0001741850 KREHER NERISSA C/O ENTRADA THERAPEUTICS, INC. 6 TIDE STREET BOSTON MA 02210 0 1 0 0 Chief Medical Officer Common Stock 2022-09-21 4 M 0 3341 2.10 A 24057 D Common Stock 2022-09-21 4 S 0 3341 15.0833 D 20716 D Common Stock 2022-09-23 4 M 0 939 2.10 A 21655 D Common Stock 2022-09-23 4 S 0 939 15.0871 D 20716 D Stock Option (Right to Buy) 2.1 2022-09-21 4 M 0 3341 0 D 2030-12-01 Common Stock 3341.0 25564 D Stock Option (Right to Buy) 2.1 2022-09-23 4 M 0 939 0 D 2030-12-01 Common Stock 939.0 24625 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2022. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.32, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.37, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. 25% of the shares subject to this option shall vest and become exercisable on December 7, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter. /s/ Jared Cohen, as Attorney-in-Fact 2022-09-23